De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Shockwave Medical Beheer

Beheer criteriumcontroles 4/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Doug Godshall

Algemeen directeur

US$9.5m

Totale compensatie

Percentage CEO-salaris	7.6%
Dienstverband CEO	7yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	2.3yrs
Gemiddelde ambtstermijn bestuur	5.3yrs

Recente managementupdates

Recent updates

Shockwave Medical, Inc.'s (NASDAQ:SWAV) 28% Jump Shows Its Popularity With Investors

Apr 06

Is Now An Opportune Moment To Examine Shockwave Medical, Inc. (NASDAQ:SWAV)?

Mar 24

Shockwave Medical: Opening Arteries, Delivering Returns

Feb 28

Shockwave Medical, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Feb 18

There's Been No Shortage Of Growth Recently For Shockwave Medical's (NASDAQ:SWAV) Returns On Capital

Feb 06

Calculating The Fair Value Of Shockwave Medical, Inc. (NASDAQ:SWAV)

Jan 24

Some Shareholders Feeling Restless Over Shockwave Medical, Inc.'s (NASDAQ:SWAV) P/E Ratio

Jan 09

Analyse CEO-vergoeding

Hoe is Doug Godshall's beloning veranderd ten opzichte van Shockwave Medical's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2024	n/a	n/a	US$163m
Dec 31 2023	US$9m	US$716k	US$147m
Sep 30 2023	n/a	n/a	US$244m
Jun 30 2023	n/a	n/a	US$244m
Mar 31 2023	n/a	n/a	US$241m
Dec 31 2022	US$8m	US$644k	US$216m
Sep 30 2022	n/a	n/a	US$88m
Jun 30 2022	n/a	n/a	US$55m
Mar 31 2022	n/a	n/a	US$29m
Dec 31 2021	US$7m	US$575k	-US$9m
Sep 30 2021	n/a	n/a	-US$38m
Jun 30 2021	n/a	n/a	-US$53m
Mar 31 2021	n/a	n/a	-US$71m
Dec 31 2020	US$5m	US$546k	-US$66m
Sep 30 2020	n/a	n/a	-US$65m
Jun 30 2020	n/a	n/a	-US$65m
Mar 31 2020	n/a	n/a	-US$57m
Dec 31 2019	US$2m	US$477k	-US$51m
Sep 30 2019	n/a	n/a	-US$48m
Jun 30 2019	n/a	n/a	-US$45m
Mar 31 2019	n/a	n/a	-US$44m
Dec 31 2018	US$511k	US$376k	-US$41m

Compensatie versus markt: De totale vergoeding ($USD 9.48M ) Doug } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 13.04M ).

Compensatie versus inkomsten: De vergoeding van Doug is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Doug Godshall (58 yo)

7yrs

Tenure

US$9,478,729

Compensatie

Mr. Douglas E. Godshall, also known as Doug, M.B.A., is Director of Saluda Medical, Inc. He serves as Chair of the Board of Galvanize Therapeutics, Inc. since September 2022. He has been the Chief Executiv...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Douglas Godshall	President	7yrs	US$9.48m	0.29% $ 36.5m
Isaac Zacharias	President & Chief Commercial Officer	1.9yrs	US$3.23m	0.15% $ 18.8m
Daniel Hawkins	Founder and Senior Advisor	15.3yrs	geen gegevens	geen gegevens
John Adams	Co-Founder and Technical Advisor	15.3yrs	geen gegevens	geen gegevens
Renee Gaeta	Chief Financial Officer	less than a year	geen gegevens	0.053% $ 6.7m
Luis Morales	Senior Vice President of Global Operations	less than a year	geen gegevens	geen gegevens
Trinh Phung	Chief Accounting Officer	2.3yrs	geen gegevens	0.13% $ 16.9m
Debbie Kaster	Vice President of Investor Relations	less than a year	geen gegevens	geen gegevens
Hajime Tada	General Counsel & Secretary	4.9yrs	geen gegevens	geen gegevens
Robert Fletcher	Senior Vice President of Marketing & Market Access	7.8yrs	geen gegevens	geen gegevens
Dave Cox	Vice President of Sales	less than a year	geen gegevens	geen gegevens
Cathy Harnett	Senior Director of Human Resources	2.3yrs	geen gegevens	geen gegevens

2.3yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SWAV wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Douglas Godshall	President	7yrs	US$9.48m	0.29% $ 36.5m
Antoine Papiernik	Independent Director	10.8yrs	US$277.06k	geen gegevens
Frederic Moll	Independent Director	13yrs	US$273.62k	0.76% $ 95.7m
Charles Larkin	Independent Chairman of the Board	5.3yrs	US$333.62k	0.012% $ 1.5m
Laura Francis	Independent Director	5.3yrs	US$297.37k	0.011% $ 1.4m
Sara Toyloy	Independent Director	3.2yrs	US$278.62k	0.0052% $ 651.0k
Maria Sainz	Independent Director	3.8yrs	US$289.87k	0.0096% $ 1.2m
Kevin Ballinger	Independent Director	less than a year	US$508.05k	geen gegevens
F. Watkins	Independent Director	10.9yrs	US$278.62k	0.010% $ 1.3m

5.3yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SWAV wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).

Shockwave Medical Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Shockwave Medical, Inc. Announces Termination of Employment of Renee Gaeta as Chief Financial Officer

Shockwave Medical, Inc., Annual General Meeting, May 29, 2024

Insufficient new directors

Chief Commercial Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Chief Commercial Officer notifies of intention to sell stock

Recent updates

Shockwave Medical, Inc. Announces U.S. Launch of the Shockwave E8 Peripheral Ivl Catheter

Shockwave Medical Files Form 15

Shockwave's Common Stock Ceases Trading on NASDAQ

Shockwave Medical, Inc. Announces Termination of Employment of Renee Gaeta as Chief Financial Officer

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Shockwave Medical, Inc. (NasdaqGS:SWAV) from a group of sellers.

Shockwave Medical Withdraws Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Shockwave Medical, Inc., Annual General Meeting, May 29, 2024

Price target increased by 7.7% to US$302

Shockwave Medical, Inc. Announces Investigators Presented Six-Month Data from the Full Population of the Reducer-I Study

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion.

Shockwave Medical, Inc.'s (NASDAQ:SWAV) 28% Jump Shows Its Popularity With Investors

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion.

Price target increased by 9.7% to US$286

Insufficient new directors

Johnson & Johnson Reportedly Considers Deal for Shockwave Medical

Chief Commercial Officer notifies of intention to sell stock

Is Now An Opportune Moment To Examine Shockwave Medical, Inc. (NASDAQ:SWAV)?

Independent Director notifies of intention to sell stock

Chief Commercial Officer notifies of intention to sell stock

Shockwave Medical: Opening Arteries, Delivering Returns

New minor risk - Shareholder dilution

Independent Director recently sold US$15m worth of stock

Now 21% undervalued

Consensus EPS estimates increase by 12%

President exercised options and sold US$2.3m worth of stock

Shockwave Medical, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Full year 2023 earnings: EPS exceeds analyst expectations

Shockwave Medical, Inc. Provides Earnings Guidance for 2024

There's Been No Shortage Of Growth Recently For Shockwave Medical's (NASDAQ:SWAV) Returns On Capital

Shockwave Medical, Inc. Appoints Renee Gaeta as Chief Financial Officer, Effective February 5, 2024

Chief Commercial Officer notifies of intention to sell stock

Calculating The Fair Value Of Shockwave Medical, Inc. (NASDAQ:SWAV)

President notifies of intention to sell stock

Shockwave Medical, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Some Shareholders Feeling Restless Over Shockwave Medical, Inc.'s (NASDAQ:SWAV) P/E Ratio

President notifies of intention to sell stock

Is Shockwave Medical (NASDAQ:SWAV) A Risky Investment?

Chief Commercial Officer notifies of intention to sell stock

President exercised options and sold US$922k worth of stock

Do Shockwave Medical's (NASDAQ:SWAV) Earnings Warrant Your Attention?

Now 21% undervalued after recent price drop

President notifies of intention to sell stock

What Is Shockwave Medical, Inc.'s (NASDAQ:SWAV) Share Price Doing?

Investor sentiment deteriorates as stock falls 25%

Shockwave Medical, Inc. Announces New Data Demonstrating One-Year Outcomes with Coronary Lithotripsy

Now 22% undervalued after recent price drop

Shockwave Medical, Inc. Provides Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 13% to US$241

Shockwave Medical, Inc. Introduces Enhanced Coronary IVL Catheter in the United States

Shockwave Medical, Inc. Announces New Shockwave Coronary IVL Publications Confirm Safety and Efficacy Across Multiple Calcium Morphologies

Is Shockwave Medical, Inc. (NASDAQ:SWAV) Trading At A 50% Discount?

President notifies of intention to sell stock

Shockwave Medical (NASDAQ:SWAV) Is Very Good At Capital Allocation

Shockwave Medical (NASDAQ:SWAV) Has A Rock Solid Balance Sheet

President notifies of intention to sell stock

Shockwave Medical, Inc. Appoints Nick West as Associate Chief Medical Officer

Daniel K. Puckett Notifies Shockwave Medical, Inc. of His Intention to Retire as Chief Financial Officer

Do Shockwave Medical's (NASDAQ:SWAV) Earnings Warrant Your Attention?

Independent Director notifies of intention to sell stock

Consensus EPS estimates fall by 10%, revenue upgraded

Shockwave Medical, Inc. Revises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Independent Director notifies of intention to sell stock

When Should You Buy Shockwave Medical, Inc. (NASDAQ:SWAV)?

We Think Shockwave Medical (NASDAQ:SWAV) Might Have The DNA Of A Multi-Bagger

Chief Commercial Officer notifies of intention to sell stock

Shockwave Medical, Inc.(NasdaqGS:SWAV) dropped from Russell 2000 Dynamic Index